Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 28

1.

Pathogenesis of persistent lymphatic vessel hyperplasia in chronic airway inflammation.

Baluk P, Tammela T, Ator E, Lyubynska N, Achen MG, Hicklin DJ, Jeltsch M, Petrova TV, Pytowski B, Stacker SA, Ylä-Herttuala S, Jackson DG, Alitalo K, McDonald DM.

J Clin Invest. 2005 Feb;115(2):247-57.

2.

Management of chronic obstructive pulmonary disease.

Sutherland ER, Cherniack RM.

N Engl J Med. 2004 Jun 24;350(26):2689-97. Review. No abstract available.

PMID:
15215485
3.

NICE guidance for COPD.

Halpin D.

Thorax. 2004 Mar;59(3):181-2. No abstract available.

4.

Longitudinal changes in the nature, severity and frequency of COPD exacerbations.

Donaldson GC, Seemungal TA, Patel IS, Lloyd-Owen SJ, Wilkinson TM, Wedzicha JA.

Eur Respir J. 2003 Dec;22(6):931-6.

5.

Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease.

Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H.

Eur Respir J. 2003 Dec;22(6):912-9. Erratum in: Eur Respir J. 2004 Dec;24(6):1075.

6.
7.

The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD.

Hanania NA, Darken P, Horstman D, Reisner C, Lee B, Davis S, Shah T.

Chest. 2003 Sep;124(3):834-43.

PMID:
12970006
8.

Economic analysis of the Confronting COPD survey: an overview of results.

Wouters EF.

Respir Med. 2003 Mar;97 Suppl C:S3-14.

PMID:
12647938
9.

Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial.

Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, Anderson J, Maden C; TRial of Inhaled STeroids ANd long-acting beta2 agonists study group.

Lancet. 2003 Feb 8;361(9356):449-56. Erratum in: Lancet. 2003 May 10;361(9369):1660.

PMID:
12583942
10.

Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease.

Szafranski W, Cukier A, Ramirez A, Menga G, Sansores R, Nahabedian S, Peterson S, Olsson H.

Eur Respir J. 2003 Jan;21(1):74-81. Erratum in: Eur Respir J. 2003 May;21(5):912.

11.

Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations.

Jones PW, Willits LR, Burge PS, Calverley PM; Inhaled Steroids in Obstructive Lung Disease in Europe study investigators.

Eur Respir J. 2003 Jan;21(1):68-73.

12.

Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study.

van der Valk P, Monninkhof E, van der Palen J, Zielhuis G, van Herwaarden C.

Am J Respir Crit Care Med. 2002 Nov 15;166(10):1358-63. Epub 2002 Sep 5.

PMID:
12406823
13.

Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease.

Mahler DA, Wire P, Horstman D, Chang CN, Yates J, Fischer T, Shah T.

Am J Respir Crit Care Med. 2002 Oct 15;166(8):1084-91.

PMID:
12379552
14.

Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial.

Aalbers R, Ayres J, Backer V, Decramer M, Lier PA, Magyar P, Malolepszy J, Ruffin R, Sybrecht GW.

Eur Respir J. 2002 May;19(5):936-43. Erratum in: Eur Respir J 2002 Jul;20(1):245.

15.
16.

Lung tissue eosinophils may be cleared through luminal entry rather than apoptosis: effects of steroid treatment.

Uller L, Persson CG, Källström L, Erjefält JS.

Am J Respir Crit Care Med. 2001 Nov 15;164(10 Pt 1):1948-56.

PMID:
11734451
17.
18.

Effects of withdrawal of inhaled steroids in men with severe irreversible airflow obstruction.

O'Brien A, Russo-Magno P, Karki A, Hiranniramol S, Hardin M, Kaszuba M, Sherman C, Rounds S.

Am J Respir Crit Care Med. 2001 Aug 1;164(3):365-71.

PMID:
11500334
19.
20.

Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease.

Seemungal TA, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA.

Am J Respir Crit Care Med. 2000 May;161(5):1608-13.

PMID:
10806163

Supplemental Content

Support Center